Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks

Pomerantz LLP has launched an investigation into Omeros Corporation (NASDAQ: OMER) to determine if the company or its executives engaged in securities fraud. The probe follows two significant regulatory setbacks regarding the marketing authorization application for narsoplimab, intended to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The investigation stems from negative opinions issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The first negative opinion was delivered in June 2026, causing a 19.12% drop in share price. A subsequent re-examination in October 2026 resulted in a second negative opinion, leading to another 13.78% decline in the company's stock value.

7 articles from 3 sources · updated

Coverage